TP53 and colorectal carcinoma: Here, we examined the therapeutic effect of LR disruption by using miltefosine in a panel of P53 WT and P53 mutant CRC cells (P53 wild type: SW48, HCT116 and hCRC1; P53 mutant: DLD1, HCT15, HT29, SW480, hCRC2, hCRC3 and hCRC4).